-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The latest data from Mi Nei.
com shows that in the first three quarters of 2021, the sales of chemical medicines in public hospitals in key cities have exceeded 130 billion yuan, a year-on-year increase of more than 10%
.
From the perspective of the urban structure, Beijing, Shanghai, and Guangzhou still rank firmly in the top three
"Beijing, Shanghai, Guangzhou" is a big hit! The "iron triangle" of foreign companies broke through, and Hengrui, Qilu, and Yangtze River broke through
"Beijing, Shanghai, Guangzhou" is a big hit! The "iron triangle" of foreign companies broke through, and Hengrui, Qilu, and Yangtze River broke throughQuarterly sales of chemical drugs in public hospitals in key cities in Q3 2020-2021 (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
According to data from Mi Nei.
com, in the first three quarters of 2021, the sales of chemical medicines in public hospitals in key cities have exceeded 130 billion yuan
.
From the perspective of quarterly sales trends, affected by the epidemic last year, it gradually recovered after experiencing a low ebb, with a year-on-year growth of more than 10% in the first three quarters of this year
From the perspective of major categories, five categories of anti-tumor and immunomodulators, digestive system and metabolic drugs, blood and hematopoietic system drugs, systemic anti-infective drugs, and neurological drugs have the most popular sales.
Among them, the first three categories The growth rate exceeded 10%
.
Chemical city structure of public hospitals in some key cities from Q1-Q3 in 2021 (unit: ten thousand yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
From the perspective of urban structure, the three major cities of Beijing, Shanghai and Guangzhou still rank firmly in the top three, among which Beijing and Guangzhou each have sales of more than 15 billion yuan
.
The market share of three domestic pharmaceutical companies in public hospitals of key cities in recent years
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
From the perspective of TOP10 manufacturers, although there are only three domestic pharmaceutical companies, Jiangsu Hengrui Pharmaceutical, Qilu Pharmaceutical, and Yangzijiang Pharmaceutical, their market share is increasing; while foreign pharmaceutical companies occupy 7 seats, and their market shares have varying degrees.
Decline
.
In terms of growth rate, Qilu Pharmaceutical has the fastest rate of over 40%, followed by Jiangsu Hengrui Pharmaceutical and Yangzijiang Pharmaceutical
TOP10 soared across the board! Qilu becomes the "growth king", and the two major centralized sourcing varieties "exit"
TOP10 soared across the board! Qilu becomes the "growth king", and the two major centralized sourcing varieties "exit"2021 Q1-Q3 Top 10 Chemical Drug Products in Public Hospitals in Key Cities
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
The TOP10 product line surged across the board, with 9 sales exceeding 1 billion yuan
.
In terms of growth rate, bevacizumab injection, iodixanol injection, dezocine injection, and pegylated recombinant human granulocyte stimulating factor injection all exceeded 20%.
The growth rate of clopidogrel bisulfate tablets and atorvastatin calcium tablets in public hospitals in key cities in recent years
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
It is worth noting that due to the impact of centralized procurement in recent years, the TOP10 products are also changing
.
Compared with 2019, iodixanol injection and rituximab injection are among the top ten; clopidogrel bisulfate tablets and atorvastatin calcium tablets have been replaced, and both products are the first batch of products.
At present, only iodixanol injection is a centralized procurement product among the TOP10 products.
Four companies including General Electric, Shanghai Stellite Pharmaceuticals, Yangzijiang Pharmaceutical Group, and Nanjing Zhengda Tianqing won the bid.
In October this year, the fifth batch of centralized procurement was completed.
What will happen to the market structure of this product if it is implemented one after another? Mi Nei Net will continue to pay attention
.
2021 Q1-Q3 Top 10 Chemical Drug Brands in Public Hospitals in Key Cities
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
Among the TOP10 brands, Yangtze River Pharmaceutical’s Dezocine Injection has been firmly in the top position; from the perspective of sales growth, only AstraZeneca’s osimertinib mesylate has a negative growth rate, and all 9 brands have Year-on-year growth, among which Qilu Pharmaceutical’s bevacizumab injection was the fastest, with a year-on-year increase of more than 200%; Sanofi’s oxaliplatin for injection and CSPC’s doxorubicin hydrochloride liposomes The growth rate of injection is more than 30%
.
In terms of the number of brands, CSPC has the most, with two
Sales of bevacizumab injection in public hospitals in key cities in recent years (unit: 100 million yuan)
Source: Mi Nei.
com's chemical drug terminal competition pattern in key cities of public hospitals
Bevacizumab injection is widely used in the treatment of a variety of malignant tumors.
It has been approved for colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma and other indications worldwide
.
According to data from Meinenet, the sales of bevacizumab injection in public hospitals in key cities have increased rapidly in recent years.
